Pharmaceuticals
First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe
SHANGHAI, Oct. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient inEurope has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company's self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination ...
2023-10-25 21:15
1674
Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell's 9MW2821 at 2023 ESMO
Shanghai, Oct. 25, 2023 /PRNewswire/ -- ESMO Congress 2023 was held in Madrid, Spain from October 20-24, the preliminary results of the Phase I/II study of 9MW2821 (Nectin-4 targeting ADC) in patients with advanced solid tumors were reported by Dr.Jian Zhang of Fudan University Shanghai Cancer Ce...
2023-10-25 17:46
1401
AMS BioteQ Makes Debut at Medical Japan 2023: Bringing Innovative Healthcare into New Horizons
TAIPEI, Oct. 25, 2023 /PRNewswire/ -- Medical Japan Tokyo was held grandly from October 11 to 13, gathering medical professionals, manufacturers, medical institutions, and research units from around the world. AMS BioteQ Co., Ltd. made its first appearance in the exhibition and became one of the ...
2023-10-25 13:06
1376
Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development
EAST RUTHERFORD, N.J, Oct. 25, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry has been selected as the winner of the API Development Award, presented at the CPhI Pharma Awards inBarcelona, Spain....
2023-10-25 04:18
1641
Cyrus K. Mirsaidi Named Global CEO to Bridgewest Perth Pharma
--Industry veteran to lead growth for company's CDMO and pharmaceutical supply divisions, NovaCina and LumaCina-- MIAMI and PERTH, Australia, Oct. 25, 2023 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, announced today thatCyrus K. Mirsaidi is ...
2023-10-24 23:17
1296
Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO
HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The ...
2023-10-24 20:00
1081
Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China
First Amyloid PET Tracer Received Regulatory Approval in China BERLIN and BEIJING, Oct. 24, 2023 /PRNewswire/ -- Life Molecular Imaging (LMI) and Sinotau Pharmaceutical Group are pleased to announce Neuraceq® (with Chinese trade name 欧韦宁®, florbetaben F-18 injection) has received regulatory appr...
2023-10-24 16:00
1220
Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection Receives U.S. FDA Approval
SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "BioRay") announced onOctober 7th that its clinical trial application for BR105 Injection has received approval from the United States Food and Drug Administration (FDA). This marks BioRay's first ...
2023-10-24 15:05
1048
OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product
Visit OBiO at ESGCT 30th Annual Congress in Brussels SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, officially announced an agreement with Refreshgene...
2023-10-24 12:05
1235
Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards
SINGAPORE, Oct. 24, 2023 /PRNewswire/ -- Juniper Biologics
2023-10-24 12:00
1189
CCTV+: Jianchangbang Pharmacy: A Thousand Years of Tradition and Excellence
BEIJING, Oct. 24, 2023 /PRNewswire/ -- As a living legacy of Jiangxi's rich culture of traditional Chinese medicine (TCM), the respected brand, Jianchangbang Pharmacy, carries forward the splendor of Chinese medical wisdom. It is a renowned sect of theSouth China ancient TCM school and TCM prepar...
2023-10-24 11:51
1426
Based on recent data presented at 2023 ESMO, the innovative TROP2 ADC SKB264 (MK-2870) shows promising prospects for the treatment of patients with HR+/HER2- metastatic breast cancer who have undergone multiple prior lines of therapy , and its clinical development in other solid tumors is also advancing steadily
CHENGDU, China, Oct. 24, 2023 /PRNewswire/ -- Human trophoblastic cell surface antigen 2 (TROP2) exhibits high expression in numerous solid tumors, making it a prominent target in recent oncology studies. The progress in the development of Antibody-Drug Conjugates (ADCs) against this target has ...
2023-10-24 10:19
2171
Alphamab Oncology updated data from two studies of KN026 in combination with docetaxel for HER2-positive breast cancer at ESMO
* KN026 combined with docetaxel has significant efficacy in the first-line treatment of HER2-positive recurrent or metastatic breast cancer, with mPFS of 26.9 months and 24-month OS rate of 84.2%. * KN026 combined with docetaxel has significant efficacy and good tolerability in the neoadjuvan...
2023-10-24 08:41
3021
XINGIMAGING and MITRO BIOTECH CO., LTD. MERGE TO DELIVER FULL-SERVICE CRO OPERATIONS TO GLOBAL RESEARCH INITIATIVES
NEW HAVEN, Conn., Oct. 23, 2023 /PRNewswire/ -- XINGIMAGING, LLC, and MITRO Biotech Co., Ltd., two recognized lead companies offering quality and excellence in drug development and imaging solutions, have merged to create one company dedicated to providing a full spectrum of CRO & CDMO research s...
2023-10-23 22:38
1406
Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023
Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all patients treated in the expansion cohort PRINCETON, N.J. and SUZHOU, China, Oct. 23, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Tr...
2023-10-23 21:48
3543
Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis
MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ...
2023-10-23 21:30
1153
Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC
SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest clinical data of it...
2023-10-23 19:56
1111
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs
SHANGHAI, Oct. 23, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces the latest clinical progress of 2 novel drugs including Nectin-4 ADC 9MW2821, as well as the clinical study data to be reported on ESMO 2023. Latest progress...
2023-10-23 18:25
1221
The team from Kelun-Biotech held a meeting with representatives from MSD in Madrid, Spain
CHENGDU, China, Oct. 23, 2023 /PRNewswire/ -- On October 20, 2023, the European Society for Medical Oncology (ESMO) Conference grandly commenced inMadrid, Spain . The ESMO Conference is the most esteemed and influential oncology conference inEurope, and this annual event garners the participation ...
2023-10-23 18:16
1503
Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer Patients
* Sunvozertinib monotherapy demonstrated superior efficacy and excellent safety in patients in the 1st line setting for advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion (Exon20ins) mutations, achieving a confirmed objective...
2023-10-23 17:34
1027
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 282 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 277 media titles]
2024-04-19 13:25
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
3869
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3823
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
2024-04-15 08:00
3088
Goldpac Exhibits at InnoEx 2024
2024-04-13 10:00
3026